Celine Wilke leaves Novartis to become ITM CMO

Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced the appointment of Celine Wilke (pictured, above) as chief medical officer (CMO), taking over from interim CMO Heike Oberwittler.

Dr Wilke holds nearly 20 years of industry experience, most recently in radiopharmaceutical drug development, most recently as senior global program clinical head for prostate cancer at Swiss pharma giant Novartis (NOVN: VX) 

While at the Basel-based company, Dr Wilke oversaw clinical trials for radiopharmaceutical therapies and imaging compounds, resulting in the global approvals of Pluvicto (Lutetium ( 177 Lu) vipivotide tetraxetan) and Locametz (PSMA-11, gozetotide).